Stocks · News reference
MaxCyte Affirms FY2026 Sales Guidance of $30.000M-$32.000M vs $31.082M Est
MaxCyte (NASDAQ:MXCT) affirms FY2026 sales outlook from $30.000 million-$32.000 million to $30.000 million-$32.000 million vs $31.082 million estimate.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
MaxCyte shares are trading higher after the company reported preliminary Q3 core revenue growth of 26% and raised its 2026 revenue guidance.
8-K filing — MAXCYTE, INC. (MXCT)
Filed: 2026-10-14 AccNo: 0001104659-26-115745 Size: 235 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
MaxCyte Reports Preliminary Q3 Core Revenue Of ~$8.1M, Up 26% YoY; Raises FY26 Revenue Guidance To ~$34M, Core Business Revenue Outlook To ~$28M
MaxCyte, Inc., (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today